Korean researchers advance commercialization of organoid treatment for intractable bowel diseases

Korea Research Institute of Bioscience and Biotechnology's Dr. Son Mi-young transfers intestinal organoid regenerative therapy technology

Dr. Son Mi-young conducts experiments on three-dimensional intestinal organoids differentiated from human pluripotent stem cells. [Korea Research Institute of Bioscience and Biotechnology]

The commercialization of organoid technology that could open new treatment possibilities for patients with intractable bowel diseases — conditions that respond poorly to medication alone — is now moving into high gear.

Organoids are organ-like structures created by culturing or recombining stem cells in three dimensions, and they closely replicate the function and structure of organs in the human body.

The Korea Research Institute of Bioscience and Biotechnology (KRIBB) said it has transferred core technology developed by a research team led by Dr. Son Mi-young — titled "Human Intestinal Organoid-Based Regenerative Therapeutics and Drug Evaluation Platform Source Technology" — to Organoid Sciences, a company specializing in organoid-based regenerative therapies. The deal is valued at 8.3 billion won (approximately $5.49 million), comprising a fixed technology fee covering upfront and milestone payments, as well as running royalties tied to future sales.

The agreement covers three core patents and accumulated know-how that Dr. Son's team has built up since developing a manufacturing technology for mature intestinal organoids derived from human pluripotent stem cells.

To bring the organoid regenerative therapy beyond the laboratory and into actual clinical use, the research team integrated three capabilities into a single unified platform: high-performance mature intestinal organoid manufacturing technology, engraftment and regenerative capacity enhancement technology, and uniform large-scale production and culture technology.

The core of the technology lies in using human pluripotent stem cells to produce mature intestinal organoids that replicate the structure and function of the human intestine, making those organoids available both as regenerative therapeutics and as a drug evaluation platform.

The team also developed technologies to improve engraftment and regenerative efficiency, alongside large-scale production and cryopreservation capabilities — advances that address longstanding limitations of conventional organoid technology in homogeneity, reproducibility and supply.

These advances lay the groundwork for developing the technology into an off-the-shelf universal cell therapy that can be deployed immediately when needed.

A signing ceremony for the technology transfer agreement between the Korea Research Institute of Bioscience and Biotechnology and Organoid Sciences. [Korea Research Institute of Bioscience and Biotechnology]

Intestinal organoid regenerative therapy represents a new approach that goes beyond conventional treatments focused on suppressing inflammation, instead inducing the regeneration of damaged tissue. It is expected to find broad application in developing treatments for intractable bowel diseases such as inflammatory bowel disease and radiation enteritis.

Organoid Sciences plans to use the technology to pursue full-scale development of regenerative therapies for intractable bowel diseases, while also expanding its application into an advanced alternative testing platform capable of evaluating drug efficacy and toxicity with greater precision.

The technology is also expected to reduce reliance on animal testing — long considered an essential step in drug development — and accelerate the drug development process.

"This technology transfer is an important starting point for the source technology in human intestinal organoids that KRIBB has accumulated to be combined with a company's commercialization capabilities and applied to actual patient treatment," Dr. Son said. "We will continue follow-up research so that this can lead to the development of regenerative therapies that provide real help to patients with intractable bowel diseases."

nbgkoo@heraldcorp.com